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ABSTRACT 
Fibromyalgia is a chronic non inflammatory musculoskeletal disorder 
characterized by a variety of symptoms related to pain. The first criterion for the 
diagnosis requires patient to report at least 3 months of widespread pain. The 
second is widespread pain in response to a tender point examination. Common 
unspecific symptoms include fatigue, nonrestorative sleep, morning stiffness, 
mood disorders, anxiety, depression, cognitive dysfunction (e.g., memory 
problems, concentration difficulties, diminished mental clarity), irritable bowel 
and bladder syndrome, sexual dysfunction and sicca symptoms. In the last few 
years many attempts have been carried out for the research of specific biomarkers 
in fibromyalgia, but, at present, there are no specific markers and the diagnosis is 
basically clinical. 
In the present work we used two complementary proteomic approaches to obtain 
the whole saliva protein map of fibromyalgia patients: two-dimensional 
electrophoresis in combination with mass spectrometry and Surface enhanced 
laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS). 
The aim of this study was the evaluation of the global changes of protein profiles 
which occur in the disease and the research for any eventual diagnostic or 
prognostic salivary biomarkers, which could be used routinely, in the future, for 
the management of fibromyalgia patients. 22 fibromyalgia patients and 26 healthy 
subjects were enrolled in the analysis with two-dimensional electrophoresis; 
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while for SELDI-TOF-MS technique saliva samples were collected from 63 
patients and 63 controls.  
With two-dimensional electrophoresis we found the significant over-expression 
of transaldolase and phosphoglycerate mutase I. These findings were validated by 
Western blot analysis and the total optical density confirmed their significant up-
regulation in fibromyalgia samples with respect to healthy subjects. It was 
noteworthy that seven further salivary proteins resulted differentially expressed: 
calgranulin A, calgranulin C, cyclophilin A, profilin 1, Rho GDP-dissociation 
inhibitor 2, proteasome subunit-a-type-2 and haptoglobin-related protein 
precursor. With SELDI-TOF-MS technique we highlighted also the presence of a 
pattern of proteins potentially useful to discriminate fibromyalgia patients from 
healthy subjects.    
These results demonstrated the utility of proteomic analysis in the identification 
of salivary biomarkers in fibromyalgia patients. 
 
 
 
 
 
 
 7 
INTRODUCTION 
FIBROMYALGIA 
Fibromyalgia syndrome (FM) is a chronic non inflammatory musculoskeletal 
disorder which can occur as a primary disease or in association with other 
autoimmune diseases (i.e. Rheumatoid arthritis, Systemic sclerosis, Sjögren’s 
syndrome, autoimmune thyroiditis, tetany and chronic fatigue syndrome). In 
1990, The American College of Rheumatology laid out several sets of criteria for 
the diagnosis of FM. [1]. The first criterion required patients to report at least 3 
months of widespread pain. Pain was considered widespread if it was present in 
four quadrants of the body, the right and left side as well as above and below the 
waist. Axial skeleton pain is also very commonly present in FM and is often 
considered a fifth “quadrant.” The second diagnostic criterion was widespread 
pain in response to a tender point examination. In this assessment the clinician 
presses on 18 specific areas, the patient’s report of pain in at least 11 of these 
tender points completes the requirements for the diagnosis of FM.  
Common unspecific symptoms associated with FM include fatigue, nonrestorative 
sleep, morning stiffness, mood disorders, anxiety, depression, cognitive 
dysfunction (e.g., memory problems, concentration difficulties, diminished 
mental clarity), irritable bowel and bladder syndrome, sexual dysfunction and 
sicca symptoms. [2, 3, 4, 5, 6]. FM has a different prevalence depending on the 
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population studies and criteria used, ranging from 0.5% and 5.0% [7], with a 
female to male ratio of approximately 9:1 [4].  
Symptoms usually appear between the ages of 20 and 55 although juvenile FM in 
patients as young as 10 years old or even less has been reported and is probably 
under-recognised [8]. The disorder may be dormant for years until triggered by 
infection, injury, physical or emotional stress or sleep disturbance [9]. Although 
the key alerting symptom is chronic widespread pain or tenderness, FM is not just 
a pain disorder. The Fibromyalgia Impact Questionnaire (FIQ; table 1) gives a 
good idea of the full range of symptoms that are regularly found. The patients fill 
out a questionnaire consisting of 10 items, from which derives a score that 
indicates the impact of the disease on life (FIQ total score), the total score reflects 
the impact of FM and ranged from 0 (no impact) to 100 (maximum impact). 
Although there is no official consensus of what constitutes a clinically significant 
score on this scale most patients diagnosed with FM have an FIQ total score of at 
least 50 (out of a maximum of 100-see table 1). Severely afflicted patients 
frequently score 70 or more [10].   
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Table 1. Fibromyalgia Impact Questionnaire (FIQ). 
 Question 1 Physical functioning 
During the past week were you able to: 
Do shopping? 
Do laundry with a washer and dryer? 
Prepare meals? 
Wash dishes/cooking utensils by hand? 
Vacuum a rug? 
Make beds? 
Walk several blocks? 
Visit friends or relatives? 
Do yard work or gardening? 
Drive a car? 
Climb stairs? 
Question 2 
In the past week, how many days did you feel good? 
(1–7) 
Question 3 
How many days last week did you miss work, including housework, 
because of fibromyalgia ? 
(1–7) 
Question 4 
When you worked, how much did pain or other symptoms of your 
fibromyalgia interfere with your ability to do your work, including 
housework? 
(No problem with work < > Great difficulty with work) 
Question 5 
How bad has your pain been? 
(No pain < > Very severe pain) 
Question 6 
How tired have you been? 
(No tiredness < > Very tired) 
Question 7 
How have you felt when you get up in the morning? 
(Awoke well rested < > Awoke very tired) 
Question 8 
How bad has your stiffness been? 
(No stiffness < > Very stiff) 
Question 9 
How nervous or anxious have you felt? 
(Not anxious < > Very anxious) 
Question 10 
How depressed or blue have you felt? 
 
Table 1. The items in question 1 are scored 0, 1, 2 or 3 for always, most of the time, 
occasionally or never. Because some patients may not do some of the tasks listed, 
they are given the option of deleting items from scoring. In order to obtain a 
comparable score for all patients, the mean of the scores for the rated items is used. 
The average score is thus 0–3. This score is multiplied by 3.33 to obtain an adjusted 
score (maximum 10). Question 2 is scored inversely of the number of days (0 ¼ 7, 1 
¼ 6, 2 ¼ 5, 3 ¼ 4, 4 ¼ 3, 5 ¼ 2, 6 ¼ 1 and 7 ¼ 0). It is multiplied by 1.43 to obtain 
an adjusted score (maximum 10). Question 3 is directly the number of days. It is 
multiplied by 1.43 to obtain an adjusted score (maximum 10). Questions 4–10 are 
visual analogue scales scored on a 100 mm line with the limits given in parentheses. 
The score (0–10) is the distance (in centimetre from the left hand end). These values 
are not adjusted. Scoring: The FIQ is scored so that a higher score indicates a greater 
impact of the syndrome. Each of the 10 items has a maximum possible score of 10. 
The maximum possible score is thus 100. 
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Autoantibodies. 
Although FM is generally regarded as a non-inflammatory and non-autoimmune 
disease, there is a broad spectrum of organ and non organ specific autoantibodies 
which have been widely detected in the patients sera [11].  
Two autoantibodies, the anti-68/48 kD and the anti-45 kD, have been reported as 
possible markers for certain clinical subsets of primary FM and chronic fatigue 
syndrome and of secondary FM/psychiatric disorders, respectively [12]. In 
particular, the anti-68/48 kD antibodies were considered to be closely associated 
with FM /chronic fatigue syndrome patients presenting with hypersomnia and/or 
cognitive disorders. Pamuk and Cakir [13] reported that thyroid autoimmunity in 
FM patients was similar in frequency to that in rheumatoid arthritis (RA) patients 
but higher in frequency when compared to the control group. Although the 
frequencies of TPO antibodies (antithyroid peroxidase) in both FM and RA 
patients were significantly higher than in the controls, the increase in the 
frequency of thyroglobulin antibodies (antithyroglobulin) was not significant. 
Thyroid autoimmunity, especially the presence of TPO antibodies, was found to 
be associated with the presence of migraine and tension headaches [13].  
Compared with healthy subjects or with patients affected by other diseases, FM 
patients present anti-polymer antibodies (APA) with contrasting results in 
literature. Wison et al. found a higher prevalence of APA (67%) in FM patients in 
the USA population [14], while Bazzichi and collaborators found a lower 
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In 1986 Dinerman and team [16] found that 14% of FM patients had a positive 
antinuclear antibody (ANA) test, 30% had a history of Raynaud’s phenomenon, 
and 18% had symptoms of Sjögren’s syndrome, but none of them progressed to a 
classic connective tissue disease [11]. Al-Allaf and co-authors [17] suggested that 
patients with FM have the same rate of positive ANA as do osteoarthritis patients 
(8.8% and 8.9%, respectively). Results from their study did not show that ANA 
are a good predictor of the future development of connective tissue disease in FM 
patients and the majority of ANA-positive patients became ANA negative on 
follow-up [11]. Recently it was reported that there was no significant difference 
in the frequency of ANA or thyroid antibodies between FM patients and controls, 
and that the risk of connective tissue diseases is not increased in FM [11, 18]. 
Other antibodies (anti-serotonin, antiganglioside and anti-phospholipids) were 
identified in FM patients compared to healthy subjects [19], but according to 
Werle and collaborators the prevalence of autoantibodies against serotonin and 
thromboplastin that they found in patients with FM has no diagnostic relevance 
[20].  
So far, nonetheless, no laboratory tests and none of the above mentioned 
autoantibodies have yet been appropriately validated for the disease.  
 
FM and inflammation.  
Based on the hypothesis that the origin of all pain is inflammation and the 
inflammatory response [21] special attention has been focused on the 
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inflammatory hypothesis of FM. Since 1988 it has been known that increased 
levels of the inflammatory transmitter substance P (SP) are found in the spinal 
fluid of FM patients [22]. 
In recent years, inflammatory cytokines have also been suggested to be involved 
in the FM syndrome. This hypothesis was based on the assumption that IL-6 and 
IL-8, release of which is stimulated by SP, may have an important role in FM 
symptoms, since IL-8 promotes sympathetic pain and IL-6 is associated with 
hypersensitivity to pain, fatigue and depression. [23, 11]. Taken together, the 
profile of pro- and anti- inflammatory cytokines in FM patients has recently 
attracted considerable attention. Several studies have focused on circulating pro-
inflammatory cytokines as possible “inflammatory markers” in FM patients. 
Higher levels of IL-8 and tumor necrosis factor-alpha (TNFα) were found in FM 
patients than in controls [24, 25]. On the other hand, results for IL-10, an anti-
inflammatory cytokine which is an antagonist of TNFα and IL-1β, appear to be 
controversial, since both increases [24] or no significant changes [25, 26] have 
been reported in serum IL-10 concentration in FM patients compared with 
healthy controls.  
The sources of inflammation triggering the FM syndrome remain to be 
elucidated. It has been proposed that FM is due to neurogenic inflammatory 
response to allergens, infectious agents, chemicals or emotional stress [21]. 
Bearing in mind that mechanical abnormalities of the cervical or lumbar spine are 
included among the possible aetiology of FM, an open question may be that neck 
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or lumbar disorders can be a source of inflammation, and thus may be one cause 
of FM rather than a consequence [23]. 
Frequently, FM and depression present symptomatic similarities. If FM and 
depression coexist, the question is whether depression must be regarded as an 
associated affection or whether it is the actual cause of the chronic pain disorders 
[27]. Several studies indicate that major depression is accompanied by the 
activation of inflammatory response, with an increased production of pro-
inflammatory cytokines [23, 28]. In fact, many FM patients are treated with 
antidepressant agents, which may suppress the production of pro-inflammatory 
cytokines, such as IFNγ, and stimulate the production of anti-inflammatory 
cytokine IL-10 [29]. However, it is known that FM and depression do not always 
coexist [27]; even different profiles of pro- inflammatory and anti-inflammatory 
cytokines between patients with or without diagnosis of depression have been 
reported. For example, Müller and co-workers [27] reported higher circulating 
levels of pro-inflammatory (IL-1α and TNFα) and anti-inflammarory (IL-10) 
cytokines in FM patients without signs of depression. However, Bazzichi and co-
workers [24] found increased levels of IL-10 and IL-1 in patients with depression, 
but they did not find differences in the circulating level of IL-8 between FM 
patients with or without depression, both of them strongly higher compared with 
the levels found in control healthy people. This finding strongly suggested that 
IL-8 may be an “inflammatory marker” for FM syndrome regardless of associated 
depression [23]. 
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FM and Genetic Factors. 
Genetic factors may predispose individuals to FM. FM in families clusters suggests 
a genetic predisposition. Environmental and psychological factors, which could 
impact various members of the same family, may contribute to the symptoms of 
the disease [30, 31, 32].  
Significant data suggest that FM is genetically related to a wide range of 
conditions subsumed under the rubric of “affective spectrum disorders” (ASD), 
including major depression disorder (MDD) and anxiety disorders, premenstrual 
dysphoric disorder, attention deficit hyperactivity disorder (ADHD), irritable 
bowel syndrome (IBS) as well as migraine and cataplexy conditions [33]. 
For example, Hudson et al. [34] concluded that patients with FM were twice as 
likely to have at least one of these other conditions, compared with individuals 
without FM.  
A recent study has refined our understanding of genetic links between mood and 
pain/somatic disorders by suggesting intriguing patterns of genetic overlap and 
environmental specificity for these conditions [33, 35]. Briefly, in a large twin 
study on the relationship between two psychiatric disorders (MDD and 
generalized anxiety disorder [GAD]) and somatic syndromes (FM, chronic fatigue, 
IBS and recurrent headache), multivariate analyses suggested the influence of two 
factors: one, most likely genetic, shared between somatic disorders, MDD and 
GAD and a second one, more specific to somatic conditions, that was more 
environmentally based [35].  
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Genes implicated in mood disorders have been identified as risk factors for FM 
and related pain states. These genes include the serotonin transporter (5HTT), the 
serotonin 5HT2A receptor, catechol-O-methyltransferase (COMT) and the 
dopamine D4 receptor. [33].  
Although not found by all studies [36], the association between FM and the “s” 
allele of serotonin transporter promoter locus (5HTTLPR) is particularly 
interesting given its association with a wide range of conditions that are risk 
factors for FM, including anxiety, neuroticism (tendency towards excessive 
emotional reactivity to stressful stimuli), MDD, Bipolar Disorder, Psychosis and 
even ADHD [33]. 
Results from several investigations indicate that a single nucleotide 
polymorphism (SNP) in the serotonin transporter (5-HTT) gene may contribute 
to enhanced pain sensitivity in patients with FM. Offenbaecher and colleagues 
[37] were the first to report that the short (S) allele of this SNP (i.e., the S/S 
genotype) in the regulatory region of the 5-HTT gene occurs significantly more 
frequently in patients with FM than in healthy controls. Cohen and colleagues 
[38] subsequently replicated this observation in an independent sample [39]. 
There also evidence that the presence of a SNP in the 5HTT gene may moderate 
the association between exposure to stressful life events and depression [39]. 
Caspi and colleagues studied young adults in a large, prospective, longitudinal 
study and found that, 1 or 2 copies of the short allele of the polymorphism 
reported more depressive symptoms and more frequently met criteria for MDD in 
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relation to stressful life events from age 21 to age 26 than those who were 
homozygous for the long allele (L/L) genotype [40]. 
Another area of investigation is the 5HT2A receptor gene; the analysis of genetic 
polymorphisms showed that the serotonin 5-HT2A receptor polymorphism T/T 
phenotype occurred more often in FM patients than in normal controls [41]. 
Interestingly, a separate study [42] noted that the same T/T allele, in the presence 
of high maternal nurturance, was associated with lower depressive symptoms 
than the C/C genotype, consistent with the notion that environmental factors 
may play a role in triggering the development of mood disorders. 
COMT is also a candidate for involvement in FM. The COMT gene encodes an 
enzyme that metabolizes catecholamines (i.e., norepinephrine and dopamine) and 
thereby influences several cognitive-affective phenotypes, including pain 
phenotypes. COMT also has been implicated in the pathogenesis of migraine and 
anxiety disorders, as well as a variety of cardiovascular diseases [39]. Initial 
studies focused on the val158met polymorphism, a SNP in codon 158 of the COMT 
gene that substitutes valine for methionine and results in reduced activity of the 
enzyme. Individuals homozygous for the met158 allele of this polymorphism 
showed a diminished mu-opioid receptor response to pain, and a stronger 
subjective experience of pain when compared to heterozygous subjects. Opposite 
effects in pain and negative affect have been found in val158 homozygotes [43]. 
Other studies have found that this COMT polymorphism may play a role in the 
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stress response, the trait of novelty seeking, cognition, MDD, schizophrenia, 
anxiety disorders and ADHD [33]. 
Finally, some reports have established a connection between FM and dopamine 
D4 receptor. For example, Buskila and colleages [44] have demonstrated an 
association between FM and the DRD4 exon III 7 repeat genotype, respect to 
healthy controls; the frequency of the 7-repeat genotype was significantly lower 
in persons with FM. Treister and collaborators [45] found an association between 
the dopamine transporter gene (DAT-1) polymorphism and cold pain tolerance. 
The results underlined the association between the DAT-1 polymorphism and a 
decrease in pain threshold.  
In conclusion, genetic studies of FM have noted alterations in genes regulating 
(likely in a convergent manner with depression and pain) monoamine and 
inflammatory signalling. It is tempting to speculate that shared genetic vulnerabilities 
towards depression and pain states may be reflected in deregulation of circuitry 
involved in modulating stress responses, pain and emotional states [33]. However, no 
single candidate gene has been strongly associated with FM. It is very likely that FM, 
depression and chronic pain have complex genetic factors, some of which may be 
shared [46]. 
 
FM and Environmental Triggers. 
Environmental factors may play a role in triggering the development of FM and a 
number of “stressors,” such as physical trauma (especially involving the trunk), 
certain infections (e.g., hepatitis C virus, Epstein-Barr virus, HIV, and Lyme 
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disease), emotional stress, catastrophic events, autoimmune disease, and other 
pain conditions have been correlated with the onset of the syndrome, [47, 48]. Of 
note, each of these stressors leads to chronic widespread pain or FM in 
approximately 5% to 10% of affected individuals. In other words, these stressors 
do not act as triggers in the overwhelming majority of individuals who regain 
their baseline state of health after experiencing infections or traumatic events 
[49]. Commonly reported psychosocial triggers include chronic stress, emotional 
trauma, and emotional, physical, or sexual abuse [4]. The effects of psychosocial 
stressors may be especially pervasive because, in addition to being associated with 
the onset of chronic widespread pain, they may also contribute to enhanced pain 
responses via involvement of the neuroendocrine system [39]. 
Owing to the fact that different “stressors” can trigger the development of this 
condition, the human stress response has been closely examined for a causative 
role. This system is primarily mediated by the activity of corticotropin releasing 
hormone (CRH) and norepinephrine [50]. 
 
The role of the peripheral and central nervous system in FM. 
Pain pathways implicated in FM have peripheral and central components. Pain 
signals are detected by peripheral nociceptive nerve endings and conveyed to 
neurons located in dorsal root ganglia (DRG). From the DRG pain information is 
conducted by lightly myelinated A-delta and un-myelinated slow C-fibers to 
secondary sensory neurons localized in the dorsal column of the spinal cord [33]. 
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Aside from functional alterations in nerve membranes and endocellular signaling, 
peripheral sensitization may occur as a result of alterations in synaptic 
connectivity resulting from sprouting of sympathetic axons within DRG (which 
may further augment pain transmission), ectopic discharges and ephaptic (direct 
electrical transfer of signal) communication. Central sensitization in neuropathic 
pain (NeP) may in part be mediated by collateral sprouting as well as damage to 
inhibitory GABA inter-neurons [33, 51]. On the other hand, there are fewer data 
to support an important role for abnormalities in peripheral or spinal cord pain 
signaling in FM. Nonetheless, some evidence does indicate potential peripheral 
contributions to the disorder [33]. For example, Salemi et al. have performed skin 
biopsies in 53 FM patients and found mononuclear and fibroblast-like cells 
adjacent to nociceptive neuronal fibres that stained positive for inflammatory 
cytokines, suggesting a role for neurogenic inflammation in the etiology of the 
FM [52]. 
After synaptic processing in the dorsal horn of the spinal cord, pain signals are 
propagated via spinothalamic (paleo-spinothalamic) and spinoparabrachial (neo-
spinothalamic) tracts to higher central nervous system (CNS) pain centres. 
Spinothalamic signals are relayed through thalamus to somatosensory cortices I 
and II (SI and SII) and associated areas, including insula, anterior cingulate cortex 
(ACC) and posterior cingulate cortex (PCC). ACC, in turn, has close bidirectional 
connections with amygdala and hippocampus [33]. Spinoparabrachial fibers 
convey information to the parabrachial nucleus in the brainstem and then on to 
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amygdala, hippocampus and hypothalamus. Ascending pain signals and 
information from supraspinal pain circuitry are integrated in the mesencephalic 
periaqueductal gray area (PAG), which also has a pivotal role in regulating 
descending pain pathways [33]. Dorsolateral prefrontal cortex (DLPFC) and 
lateral-orbital prefrontal cortex (LOPFC) appear to initiate the descending pain 
modulatory sequence, explaining how attention and anticipation may influence 
the intensity of pain [33]. These prefrontal areas, richly innervated by dopamine 
fibers, can trigger opioid release in PAG, substantially reducing the intensity of 
experienced pain [33]. 
Imaging studies have consistently identified several brain areas as having a major 
role in pain processing, including primary and secondary somatosensory cortices 
(S1 and S2), thalamus, insula, ACC and PFC [33]. Together these brain areas are 
commonly referred to as the “pain matrix” [53] and many studies indicate that 
function is disrupted in this matrix in the context of chronic pain states, including 
FM.  
For example, Bailiki et al. utilized functional magnetic resonance imaging (fMRI) 
to study chronic back pain patients. Functional neural imaging enables 
investigators to visualize how the brain processes the sensory experience of pain. 
These authors reported an association between the intensity of spontaneous pain 
and activation of medial prefrontal cortex (mPFC) [54], an area known to have a 
role in automatic emotional regulation [55]. On the other hand, in this 
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population, duration of pain was most strongly associated with increased activity 
in the insula [54].  
A second fMRI study noted a greater activation in DLPFC and ACC in response to 
nonpainful stimuli in patients with FM relative to control subjects, a finding 
likely to reflect alterations in processes central to the cognitive and emotional 
aspects of pain, such as attention and anticipation [56]. In response to an 
equivalent pressure stimulus, patients with FM have been shown to demonstrate 
increased activity in several areas of the CNS pain matrix when compared to 
normal control subjects, including S2, insula, posterior cingulate cortex (PCC), 
ACC, superior temporal gyrus and inferior parietal lobule [57]. Moreover, mild 
pressure applied to subjects with FM elicited subjective pain and cerebral 
responses similar to the responses seen in normal subjects when twice as much 
pressure was applied [57]. fMRI studies like these provide objective evidence of 
altered cerebral processing of painful stimuli in FM patients. 
In addition to functional differences, several studies have found significant 
structural changes in the brains of FM patients. Kuchinad and co-workers 
reported significantly reduced gray matter density in the cingulate cortex, insula, 
mPFC and the para-hippocampal lobe of FM patients when compared to a control 
group [58]. As with depression, the physiological changes that accompany FM 
may themselves damage brain structures over time, given that in this study 
duration of illness correlated with greater gray matter changes, such that each 
year of disease had an impact equivalent to 9.5 times the loss due to normal aging 
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[33]. Changes in these areas appear to contribute to the compromised pain 
regulation, emotional modulation, stress responsivity and cognitive functioning, 
often described in FM patients [58]. For example, Luerding et al. reported that 
neurocognitive deficits in FM patients correlated with reduced gray matter 
volume in DLPFC and ACC (areas typically associated with executive function), 
additionally pain scores were noted to be negatively correlated with gray matter 
volume in mPFC [33, 59]. 
 
Diagnosis and Therapy. 
Currently, there is no therapy formally approved by the European Agency for the 
Evaluation of Medicinal Products or by the US Food and Drugs Administration 
for treatment of the pain of FM or the syndrome as a whole [23]. Treatment is 
largely empiric, although experience and small clinical studies have proved the 
efficacy of low-dose antidepressant therapy and exercise [60]. Nowadays, 
treatment of the FM syndrome includes both pharmacologic and non-
pharmacologic therapies. Pharmacologic therapies are based on antidepressants, 
analgesics, muscle relaxants and antiepileptics. Non-pharmacologic therapies 
include exercise, massage, cognitive behavioural therapy etc [61]. Today non-
pharmacological therapies, such as exercise, are recommended in the 
management of FM symptoms together with pharmacological treatment. In fact, 
it has been shown that aerobic exercise training improves physical function, 
psychological distress and other quality of life parameters in FM patients. 
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However, non-pharmacological therapies cannot replace pharmacological ones 
yet. 
The difficulty with making a formal diagnosis of FM is that laboratory tests are 
normal and many of the symptoms mimic those of other conditions including 
many rheumatic complaints, psychiatric conditions and other somatic disorders. 
It is therefore important to exclude rheumatic disorders before proceeding to a 
diagnosis of FM. It has been estimated that it takes an average of 5 years from the 
time the patient’s first reports symptoms to the time when FM is formally 
diagnosed [10, 62]. 
In spite of the alterations found in the different studies and although some 
criteria were established to standardize patients for research studies, the diagnosis 
of FM is basically clinical [63] and the lack of easily accessible laboratory 
measures makes difficult to collect under the term of FM, patients presenting 
with homogeneous features and prognosis [64, 65]. At present, there are no 
specific markers of FM, and many of them are used only to understand the 
pathogenetic mechanisms and to identify patient subgroups.  
Therefore it is desirable to identify precise biomarkers of FM according to 
feasibility and reproducibility criteria, for diagnostic and therapeutic purposes 
[63]. 
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PROTEOMICS 
In the last few years, it has become widely recognized that the genome only 
represents the first layer of complexity. Biological function is carried by the 
dynamic population of proteins, moreover, only the characterization of the 
proteins themselves can reveal posttranslational modifications (e.g., 
phosphorylation, sulfation, glycosylation, ubiquitination, and methylation) and 
give insight into protein-protein interactions and subcellular localization, thus 
providing clues about function. For these reasons, there is increasing interest in 
the field of proteomics: the large-scale identification of proteins contained in 
cells, tissues or body fluids [66]. The proteome was originally defined as the 
complete protein complement expressed by a genome [67]. However, this 
definition does not take into account that the proteome is a highly dynamic 
entity that will change based on cellular state and the extracellular milieu. 
Therefore, the definition of a proteome should specify that it is the protein 
complement of a given cell at a specified time, including the set of all protein 
isoforms and protein modifications [68].   
Proteomic analyses can be used to identify the protein content in complex 
biological samples such as biological fluids and tissue extracts, and to determine 
the quantitative or qualitative differences for each polypeptide contained in 
different samples. It is expected that the proteomic profiling patterns resulting 
from such analyses define comprehensive molecular signatures in health and 
disease [69]. The exploitation of a proteomic approach for the study of different 
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diseases has led to the hypothesis that multiple biomarkers or a panel of 
biomarkers shown by proteomic profiling may correlate more reliably with a 
specific disease than a single biomarker or protein. Expression pattern of a known 
biomarker or correlation of expression of several known biomarkers can be a 
valuable research and clinical tool for monitoring disease or treatment 
progression [70]. 
For our study we used two complementary proteomic technique: two-
dimensional polyacrylamide gel electrophoresis (2-D PAGE) and surface 
enhanced laser desorption ionization time of flight mass spectrometry (SELDI-
TOF/MS). 
 
Two-dimensional electrophoresis. 
The identification of proteins from complex biological sample has traditionally 
been performed using 2-D PAGE coupled with mass spectrometry (MS). Two-
dimensional electrophoresis (2-DE) separates proteins by both their isoelectric 
point (pI) and molecular weight. With this technique proteins are resolved into 
discrete spots, each of which represents a single protein that can be selectively 
excised and identified by MS. The high resolution of 2-DE allows the researcher 
to pick only the proteins of interest while bypassing the more abundant or less 
interesting proteins [71]. 
 
 26 
Sample preparation.  
Preparation of samples for 2-D PAGE involves solubilization, denaturation and 
reduction to completely break up the interactions between the proteins [72]. 
Although desirable, there is no single method of sample preparation that can be 
universally applied due to the diverse samples which are analyzed by 2-DE gel 
electrophoresis [73]. The ideal sample solubilization procedure for 2-D PAGE 
would result in the disruption of all non-covalently bound protein complexes and 
aggregates into a solution of individual polypeptides [74]. However, whatever 
method of sample preparation is chosen, it is most important to minimize protein 
modifications which might result in arte-factual spots on the 2-DE maps [73]. 
Samples containing urea must not be heated as this may introduce considerable 
charge heterogeneity due to carbamylation of the proteins by isocyanate formed 
from the decomposition of urea. Generally speaking, samples should be subjected 
to as minimum handling as possible and kept cold at all times [75].  
Protein extracts should not be too diluted to avoid loss of protein due to 
adsorption to the wall of the vessel (glass or plastic). If samples are rather diluted 
and contain relatively high concentrations of salts which can interfere with IEF, 
samples may be desalted [73].  
Alternatively, proteins can be precipitated with ice-cold TCA / acetone to remove 
salts. Diluted samples with a low salt concentration may also be applied directly 
without further treatment, if the dried IPG strips are reswollen in sample 
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solution. In this case, solid urea, CHAPS and dithiothreitol (DTT) are added to 
the sample until the desired concentration is obtained [73, 76]. 
 
First dimension. 
Iso-electro focusing (IEF) represents the first dimension of 2-DE and it is 
performed in individual immobilized pH gradients (IPG) strips. Each sample 
protein applied to an IPG strip will migrate to its isoelectric point (pI), the point 
at which its net charge is zero. There are strips with broad or narrow pH gradient 
(e. g., 3-10; 4-7; 4-9; 6-10; 5-6; 9-12; 10-12). 
Dried gel strips containing immobilized pH gradient were commercially 
introduced in 1991 (Pharmacia Biotech, Immobiline® DryStrip Gel), their 
adoption for the first dimension of 2-DE has produced significant improvement 
over the classical O’ Farrell carrier ampholyte-based 2-DE separation [77]. In the 
original 2-DE the required pH gradient is established by the migration of 
individual species of carrier ampholytes to their respective pI. Variations of the 
complex carrier ampholyte mixtures result in variations in the shape of the pH 
gradient [77]. The use of commercially prepared IPG DryStrip, introduced by 
Bjellqvist et al. [78]. and Gorg et al. [79] eliminates these variations.  
The pH gradient is immobilized by covalent incorporating Immobiline® 
acrylamido buffers into the acrylamide matrix during polymerization. Since 
Immobiline consists of discrete, relatively simple molecules, they can be 
manufactured very reproducibly pure, eliminating batch effect as demonstrated 
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by interlaboratory comparison [77, 80]. Further, pI resolution to 0.01 pH unit can 
be achieved [78]. The acrylamide matrix with the Immobiline, acrylamido buffers 
is cast onto a backing sheet, polymerized, washed and dried. The backing gives 
the strips size stability and simplify handling. The dried strips can be rehydrated 
in various buffers and additives that would inhibit polymerization if included at 
the time of casting [77]. 
 
Second dimension. 
Prior to the second dimension (Sodium Dodecyl Sulphate PolyAcrylamide Gel 
Electrophoresis-SDS-PAGE), the IPG strips are equilibrated twice with gentle 
shaking in a solution containing urea and glycerol in order to diminish 
electroendosmotic effects [79] which are held responsible for reduced protein 
transfer from the first to the second dimension. DTT, a reducing agent, is added 
to the first and iodoacetamide (IAA) to the second equilibration step [81]. IAA is 
added to the equilibration buffer in order to remove excess DTT (responsible for 
the "point streaking" in silver stained patterns) [82]. After equilibration the strips 
are applied to vertical SDS gels in order to perform electrophoresis and to 
separate proteins according to their molecular weight. Polypeptides separated can 
be visualized by Coomassie Blue, silver staining, fluorescence or autoradiography, 
or by "specific" stains such as glycoprotein staining or immunochemical detection 
methods [73]. Whereas the "general" protein stains are carried out in the 
electrophoresis gel directly, immunochemical detection methods are usually 
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performed after electrophoretic transfer ("blotting") of the separated polypeptides 
from the electrophoresis gel onto an immobilizing membrane [83, 84]. Silver 
staining methods are about 10-100 times more sensitive than various Coomassie 
Blue staining techniques. Consequently, they are the method of choice when 
very low amounts of protein have to be detected on electrophoresis gels. A huge 
number of silver staining protocols have been published, based on the silver 
nitrate staining technique of Merril et al. [85] and modifications. 
Stained spots excised from the electrophoresis gel can be identified by mass 
spectrometry.  
 
Mass Spectrometry, MALDI-TOF-MS. 
In traditional protein chemistry, proteins were identified by de novo sequencing 
using automated Edman degradation. Today, this technique is replaced by mass 
spectrometry, which is becoming one of the most powerful techniques in protein 
chemistry. The reason for this is a 100 fold increase in sensitivity and 10 fold 
increase in speed. Until today, the matrix assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF-MS) has been the most 
widespread technique used for protein identification [86, 87].  
Spots of interest are excised from the gel and treated with tripsin, an enzyme that 
cleaves C-terminal to arginine (R) and lysine (K). The mixture of protein 
fragments (peptides) obtained after digestion is purified and subjected to mass 
analysis. 
 30 
Basically, a mass spectrometer consists of three parts. In the first part (ion source) 
the molecules to be analysed are ionised. The energy required for ionization of 
the ions is provided by a laser (wavelength 337 nm). Once ionised the molecules 
are accelerated and fly into the next part of  the mass spectrometer, the analyser. 
Here the individual ions are separated based on the size and charge of the 
molecule. The last part of the instrument is a detector, which records the signals 
from all ion [86]. 
Before transferred into the ionisation source the peptide or protein samples are 
mixed with a matrix and the mixtures are placed to crystallize in small droplets 
on a target. The matrix is an organic component like sinapinic acid (SPA), 
dihydroxy benzoic acid (DHB), or α-cyano hydroxy cinnamic acid (HCCA). The 
choice of matrix material and the method used depends on the sample and on the 
sizes of the expected peptides.  
The MALDI source is conveniently interfaced to a time-of-flight (TOF) analyzer. 
In the TOF-analyzer the m/z ratio of the individual ions is measured based on the 
flight time in a field-free drift tube. The m/z ratio of a peptide is calculated based 
on the energy equation E=½mv2 (E=kinetic energy of the ion, m=mass, 
v=velocity).  At a constant energy, peptides with a high mass will have a longer 
flight time in the tube before it reaches the detector at the end of the flight tube. 
Therefore, the peptides are sorted due to the size of the individual peptides. Flight 
times of ions are inversely proportional to their molecular mass. However, 
constant energy is an assumption. There is a small spread of time and kinetic 
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energy during ionization. An ion mirror (a reflectron) and a time-lag focusing 
(delayed extraction) are two approaches built into the MALDI-TOF instruments 
today to overcome this problem [86].  
This technique offers a fingerprint unique for the particular protein or protein 
mixtures. The spectrum obtained is a graph of ion abundance versus the mass-to-
charge ratio. The experimental obtained mass-to-charge (m/z) values can be 
matched against theoretical obtained mass data from already identified protein 
sequences and a score depending on the correlation can be given. 
Correct identification of course requires that the database contain the specific 
protein sequences, therefore, the approach is best suited for generically well 
characterized organisms where the entire genome is known, but can also be used 
for organisms were only part of the genome is known or for which very 
homologous sequences are available. 
MALDI is ideal for biological samples because it is compatible with buffers such 
as phosphate and Tris and low concentrations of urea, non-ionic detergents, and 
to a small degree alkali metal salts, however contaminants lower the sensibility of 
the spectra. When analyzing small amounts of biological analytes using MALDI-
MS, optimizing sample preparation and removing contaminants from the sample 
can improves the spectra a lot [86, 87].       
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SELDI-TOF-MS. 
Surface enhanced laser desorption ionization time of flight mass spectrometry 
(SELDI-TOF-MS; by Bio-Rad Laboratories) is a high throughput technique, 
particularly appropriate for the investigation of low-molecular weight proteins 
(<of 25 KDa) with femtomole sensitivity and the ability to examine native 
proteins that provides a complementary visualization technique of the 2-DE. 
Furthermore SELDI-TOF-MS allows multiple samples to be analysed in a 
relatively short time while 2-DE permits the analysis of a little number of 
samples. 
The principle of this technique is very simple [88]; a few microliters of a sample 
of interest are deposited on the spots of Protein Chip Arrays that present 
chromatographic surfaces with different physiochemical characteristics 
(hydrophobic, cationic, anionic and presenting metal ion) to obtain a broad range 
of proteins bound for analysis. The Protein Chip Arrays are incubated and then 
washed with the appropriated buffer. The proteins are captured on the 
chromatographic surface by depending on their properties and analyzed by TOF 
mass spectrometry. The result is a spectrum comprised of the mass to charge 
(m/z) values and intensities of the bound proteins/peptides. One of the unique 
strengths of SELDI-TOF is its ability to analyze proteins from a variety of crude 
sample types, with minimal sample consumption and processing [89]. 
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ProteinChip® Arrays. 
ProteinChip arrays are available with a variety of chromatographic surfaces. 
Typically, chromatographic surfaces are used for profiling of proteins and 
peptides in differential expression analyses.  
The ProteinChip Q10 array: it is a strong anion exchange that can be used to 
analyze molecules with a negative charge on the surface. The active spots contain 
cationic, quaternary ammonium groups that interact with the negative charges on 
the surface of target proteins, e.g., aspartic acid or glutamic acid. By maintaining 
the pH of the binding/wash buffer at alkaline conditions (e.g., pH 8.0), an overall 
net negative charge is imparted on a greater number of proteins within the 
sample, and the result is more binding. By decreasing the pH of the binding/wash 
buffer, an overall net positive charge is imparted on the proteins, resulting in less 
binding (i.e., more specificity). 
ProteinChip CM10 array: it is a weak cation exchange that can be used to analyze 
molecules with a positive charge on the surface. The active spots contain weak 
anionic carboxylate groups that interact with the positive charges on the surface 
of target proteins, e.g., lysine, arginine or histidine residues. By decreasing the pH 
of the binding/wash buffer, an overall net positive charge is imparted on a greater 
number of proteins within the sample and the result is more binding. By 
increasing the pH of the binding/wash buffer, an overall net negative charge is 
imparted on the proteins, resulting in less binding (i.e., more specificity). Binding 
of proteins to ProteinChip CM10 arrays can also be affected by changing the ionic 
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strength of the buffer. By increasing the ionic strength, competition is generated 
between the charged protein on the surface and the buffer ions, causing weakly 
bound proteins to elute from the array surface (i.e., more specificity).  
ProteinChip IMAC30 array: it is used to capture molecules that bind polyvalent 
cationic metals such as nickel, gallium, copper, iron, and zinc. The active spots 
contain nitrilotriacetic acid (NTA) groups on the surface that chelate metal ions. 
Proteins applied to the array surface may bind to the chelated metal ion through 
histidine, tryptophan, cysteine, and phosphorylated amino acids. To generate 
selectivity, the binding and/or wash buffers may contain increasing 
concentrations of competitors (e.g., imidazole), which compete with the metal on 
the NTA group for binding to the protein or peptide.  
ProteinChip H50 array: it is an hydrophobic surface that is used for capturing 
proteins and peptides through reversed-phase or hydrophobic interactions. 
Active spots contain methylene chains that closely mimic the characteristics of 
C6 to C12 alkyl chromatographic sorbent. 
Proteins less hydrophobic relative to the binding buffer will not bind to the array 
surface, while proteins more hydrophobic will bind to the array surface. By 
increasing the organic content of the wash buffer, the hydrophobic nature of the 
buffer increases. Proteins that had previously bound to the array will divide into 
the wash buffer and be washed away if their hydrophobicity is less than that of 
the wash buffer. Only the most hydrophobic proteins will be retained with wash 
buffers containing a high concentration of organic solvent [Bio-Rad Laboratories]. 
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Desorption, Ionization, and Analysis in the ProteinChip SELDI Reader. 
The technique relies on time-of-flight mass spectrometry for the accurate 
measurement of the mass-to-charge ratio (m/z) of peptides and proteins. 
The ProteinChip SELDI reader utilizes a nitrogen laser that induces both protein 
ionization and a change of state from the solid, crystalline phase into the gas 
phase. Therefore the analyte can move very rapidly, or fly, upon application of a 
voltage differential. The voltage differential applies the same kinetic energy to all 
of the analytes in the sample, thus resulting in flight times that depend upon the 
mass (see the mass spectrometry chapter above). The ProteinChip SELDI reader 
records the TOF of the analyte; from this measurement, a highly accurate and 
precise mass is derived [Bio-Rad Laboratories].  
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SALIVA 
In terms of disease diagnosis and prognosis, a human body fluid (e.g., blood, 
urine, or saliva) appears to be more attractive than tissue because body fluid 
testing provides several key advantages including low invasiveness, minimum 
cost, and easy sample collection and processing [69, 90]. Serum or plasma have 
been the fluids most often used in disease diagnosis but an issue with these 
samples is sample preparation and handling. Another critical point is the 
complexity of the proteome [90]. Most importantly, when searching for 
biomarkers in blood, there are two serious consideration. First, the concentration  
of substance can vary over 9 orders of magnitude, which severely diminishes the 
likelihood of detecting those at the lower end of the scale; besides, blood is 
composed of peptides, proteins and cells that have half-lives ranging from seconds 
to weeks, or even a month or more. As a consequence, the presence of a given 
substance might not accurately reflect the current state of the organism [91]. 
By contrast, human saliva is becoming a more attractive source for proteomic 
profiling because it can provide clues to local and systemic diseases and 
conditions. The physiology of the oral cavity is such that the flow of secreted 
fluid is continually flushing and refreshing the fluid content of the mouth. 
Therefore, the composition of the saliva temporally reflects the metabolic activity 
of the secretory elements generating that fluid at any moment [91]. The logistical 
advantages of salivary diagnostic are obvious; saliva is relatively easy to collect in 
sufficient quantities for analysis, and the costs of storage and shipping tend to be 
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lower than those for serum and urine. Non-invasiveness, and ease of sample 
processing are advantageous as well [69, 90, 92]. In addition, for health care 
professionals and scientists, saliva tests are safer than blood tests, which are more 
likely to result in exposure to HIV or hepatitis [90]. On the other hand, a variety 
of factors may influence the rate of salivary flow and its physiologic 
characteristics, including circadian rhythms and activities such as exercise, and 
these factors should be taken into account when saliva is used as a diagnostic fluid 
[92].  
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AIM 
In the present work, for the first time, we used 2-DE in combination with MS 
and SELDI-TOF-MS to obtain the whole saliva protein map of FM patients. The 
aim of this study was the evaluation of the global changes of the protein profiles, 
which occur in the disease and the research for any eventual diagnostic or 
prognostic salivary biomarkers, which could be used routinely, in the future, for 
the management of FM patients. 
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MATERIAL AND METHODS 
Chemicals. 
Iodoacetamide (IAA), CHAPS, urea, thiourea, glycerol, SDS, TEMED, ammonium 
persulfate, glycine, 30% acrylamide-N,N,N-bisacrylamide, trifluoroacetic acid 
(TFA), HEPES and copper sulphate were acquired from Sigma-Aldrich (St. Louis, 
MO, USA). Sodium chloride (NaCl), acetonitrile (ACN) from J.T. Baker. Sodium 
acetate, Trizma base, SDS, DTT and trichloroacetic acid (TCA) from AppliChem. 
IPGs pH 3–10 L, pharmalyte 3–10 and dry strip cover fluid were purchased from 
GE Health Care, Europe (Uppsala, Sweden). Coomassie Brilliant Blue G 250 was 
from Merck (Darmstadt, Germany). Transaldolase (T-20) and phosphoglycerate 
mutase I (PGAM1) specific primary antibodies were from Santa Cruz 
Biotechnology (CA, USA). Secondary antibodies (horseradish peroxidase (HRP)-
conjugated), donkey anti-goat and goat anti-mouse, were from Santa Cruz 
Biotechnology and from PerkinElmer, respectively. DC and RC/DC protein assay 
kit, chips CM10 and IMAC30, sinapinic acid (SPA) were provided by Bio-Rad. All 
other reagents were supplied by standard commercial sources and were of the 
highest grade available. 
 
Human subjects. 
A total of 85 patients were consecutively recruited from Department of Internal 
Medicine, Rheumatology Unit, University of Pisa; (Dr Laura Bazzichi).  
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Twenty-two women with a diagnosis of FM (mean age 43.38±13.23 years, M±SD), 
made according to the ACR criteria for the disease [1], were enrolled in the study 
of two-dimensional electrophoresis. Twenty-six healthy women, with similar 
mean age (48.57±8.22; M±SD) and demographic characteristics, were included as 
controls.  
For Western blot and SELDI-TOF-MS analysis saliva samples were collected from 
sixty-tree patients (mean age 45.39±11.09 years, M±SD; 55 females, 8 males), with 
a diagnosis of FM made according to the ACR criteria and sixty-tree healthy 
subjects (mean age 40.92±10.03 years, M±SD; 47 females, 16 males).  
This study was approved by the local Ethics Committee. An informed consensus 
was obtained for diagnostic or clinical purposes. Medical history and physical 
examination of each patient was carefully recorded focusing in particular on the 
number of tender points at the time of sample collections. Patients were also 
asked to fulfil the FIQ and a visual analogue score scale (VAS) in order to assess 
their overall pain levels. Moreover, as far as serological data is concerned, 
complete blood tests, nonorgan-specific autoantibodies (Antinuclear antibodies. 
ANA; Extractable Nuclear Antigen, ENA; Rheuma-test, Ra-test; Anti-cardiolipin 
antibodies, ACLA) and thyroid hormones and thyroid specific autoantibodies 
were detected in all the cases. Hepatitis B and hepatitis C infections were 
excluded in all the participants. Patients affected by secondary FM who were 
affected by FM and any other concomitant defined systemic connective disorders 
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were excluded from the study. Patients with serious hepatic, cardiac, renal or 
lung comorbidities were also not included in the study.  
Finally, every FM patient had a psychiatric specialist evaluation to assess the 
presence of psychiatric concomitant disorders. This psychiatric evaluation was 
based on the administration of the Structured Clinical Interview for DSM-IV  
(Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition) axis-I 
disorders (SCID-I/P) [93]. 
The clinical and serological data of the patients have been summarized in tables 
2-4.  
 
Table 2: Clinical and serological features of FM patients enrolled in the study of 2-DE. 
 CLINICAL/SEROLOGICAL FEATURES  
 Patients number/sex 22/F   
 Age (years) 43.38±13.23 (mean value ± SD)  
 Xerostomia 9/22 (41%)  
 ANA 7/22 (32%)  
 Autoimmune thyroiditis 10/22 (45%)  
 Drugs potentially inducing 
xerostomia 
19/22 (86%) 
 
 Fibromyalgia Impact Questionnaire 66.8±14.4 (mean value ± SD)  
 Pain VAS (visual analogic scale) 7.9±1.9 (mean value ± SD)  
 Tenders points 14±3 (mean value ± SD)  
 
Table 3: Clinical and serological features of FM patients enrolled in the WB and SELDI-
TOF-MS analysis. 
 CLINICAL/SEROLOGICAL FEATURES  
 Patients number/sex 55/F   8/M   
 Age (years) 45.39±11.09 (mean value ± SD)  
 Xerostomia 28/63 (44%)  
 ANA 16/63 (25%)  
 Autoimmune thyroiditis 29/63 (46%)  
 Drugs potentially inducing 
xerostomia 
52/63 (83%) 
 
 Fibromyalgia Impact Questionnaire 68.5±194 (mean value ± SD)  
 Pain VAS (visual analogic scale) 7.8±2.1 (mean value ± SD)  
 Tenders points 15±3 (mean value ± SD)  
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Table 4: Results of psychiatric evaluation  
FM patients enrolled in the study of 2-DE 
PSYCHIATRIC COMORBIDITIES 8/22 (36%) 
Depression 4/22 (18%) 
Anxiety Disorder 3/22 (14%) 
Panic Disorder 1/22 (4.5%) 
FM patients enrolled in the WB and SELDI-TOF-MS analysis 
PSYCHIATRIC COMORBIDITIES 26/63 (41%) 
Panic Disorder 10/63 
2/10 
1/10 
(16%) 
Eating Disorder 
Depression 
Anxiety Disorder 6/63 
2/6 
(9.5%)  
Depression 
Depression 5/63 (7.9%) 
Bipolar Disorder 4/63 
1/4 
(6.3%) 
 Panic Disorder  
Eating Disorder 1/63 (1.6%) 
 
 
Sample collection and preparation. 
Unstimulated WS samples were collected early in the morning in standard 
conditions, i.e. all the subjects were asked no to eat (including gum or candies), 
smoke or drink since the night before. About 2 ml of saliva were obtained from 
each subject, processed immediately and kept on ice in order to minimize 
proteins degradation. Immediately after collection, saliva samples were 
centrifuged at 17000 g for 30 min at 4°C to discard bacteria, exfoliated epithelial 
cells and debris. The resulting supernatants were stored at -80°C until use. The 
protein amount was determined using Bio-Rad DC-protein assay. Bovine serum 
albumin (BSA) was used as a standard. 
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2-DE analysis. 
For analytical gels, 150 μg of proteins, for each sample, were filled up to 350 µl in 
7M urea, 2M thiourea, 4% CHAPS, 60mM DTT, 0.5% 3-10 ampholytes and 
0.002% bromophenol blue (rehydration solution). Isoelectrofocusing (IEF) was 
carried out by using 18 cm Immobiline Dry-Strips (GE Healthcare) with a linear, 
pH 3-10, gradient. IEF was performed at 16°C on an Ettan IPGphor II apparatus 
(Amersham Biosciences), according to the following schedule: the samples were 
applied by in-gel rehydration for 10 h using low voltage (30 V), then the voltage 
was linearly increased from 200 to 5000 during the first 4 h, and then the proteins 
were focused for up to 70 000Vh at a maximum voltage of 8000 V. To prepare the 
IPG strips for the second dimension, the strips were first equilibrated 15 min at 
room temperature in a buffer containing 50 mM Tris-HCl, pH 8.8, 6 M Urea, 30% 
glycerol, 2% SDS, 0.002% bromophenol blue, 1% DTT, followed by a second 
equilibration for 10 min in the same buffer except that DTT was replaced by 2.5% 
IAA. Subsequently, the IPG strips were applied horizontally on top of 12.5% 
SDS-polyacrylamide gels (20x18x0.15 cm) and electrophoresis was performed 
using the PROTEAN-II Multi Cell system (Bio-Rad) with constant amperage 
(40mA/gel) at 10 °C until the dye front reached the bottom of the gel (about 5 h) 
applying a continuous buffer system. 
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Staining and image analysis. 
The analytical gels were stained with ammoniacal silver nitrate. The procedure of 
silver staining consists of five sequential phases including protein fixation, 
sensitization, silver impregnation, image development and stopping. To ensure 
that the spot staining was within the values of the linearity range, the silver stain 
was performed in standard conditions of time and temperature. All solutions were 
kept at 4 °C, except for silver solution, while room temperature was controlled at 
18 °C. All steps were performed on an orbital shaker.  
Briefly, at the end of the second dimension run, the gels were removed from the 
glass plates, washed in deionized water for 5 min, soaked in ethanol: acetic acid: 
water (40: 10: 50) for 1 hour and then soaked in ethanol: acetic acid: water (5: 5: 
90) overnight. After protein fixation, the gels were washed in deionized water for 
5 min at 4°C and soaked in a solution containing glutaraldehyde (1%) and sodium 
acetate (0.5 M) for 30 min. After washing 3 times in deionized water for 10 min at 
4 °C, the gels were soaked twice in a 2.7 naphtalene-disulfonic acid solution 
(0.05% w/v) for 30 min at 4 °C in order to obtain homogeneous dark brown 
staining of the proteins. Then the gels were rinsed 4 times in deionized water for 
15 min at 4 °C. Staining was carried out in a freshly made ammoniacal (30%) 
silver nitrate (2.5%) solution for 30 minutes at 18 °C. After staining, the gels were 
washed 4 times in deionized water for 4 min at 4 °C. The images were developed 
in a solution containing citric acid (0.01% w/v) and formaldehyde (0.1% v/v) for 5 
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minutes. Development was stopped with a solution containing Tris (0.4M) and 
acetic acid (2% v/v).  
The stained gels were scanned using an Epson Expression 1680 Pro scanner and 
the images were analyzed using Image-Master 2D Platinum 6.01 (GE Health Care 
Europe, Uppsala).  
Spots were automatically detected, manually edited and then counted. After spot 
detection in gels, a match set and a synthetic image for each class was generated. 
A synthetic gel was obtained by averaging the positions, shapes, and optical 
densities of the matched spots in the set of gels class. This produces an 
intersection of all the gels, showing only the spots found in almost 75% of the 
images of each class.  
 
Statistical analysis. 
The optical density of the proteins was expressed as a percentage of the volume 
(mean±SD) of the spots representing a certain protein that was determined in 
comparison with the total number of proteins present in the 2-DE gel. The 
significance of the differences (p-value<0.05) was calculated using Mann-
Whitney test and Spearman’s Correlation for non-parametric variables. The 
sensibility and specificity of the potential disease biomarkers was assessed by 
receiver operating characteristic (ROC) curves. (MedCalc 9.6.4.0 software). 
Exclusively the proteins whose expression showed over two-fold spot quantity 
change in FM samples compared with control samples were selected and 
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identified by matrix-assisted laser desorption ionization time-of-flight/time-of-
flight (MALDI-TOF/TOF).  
 
Preparative gels. 
In order to identify these proteins of interest, preparative gels are performed and 
stained with Coomassie Brilliant Blue G-colloidal. This detection method is 
compatible with mass spectrometry but less sensitive than silver staining 
therefore, for preparative gels, we had to load 1500μg of proteins. Protein 
precipitation is required to prepare a concentrated protein sample from a dilute 
sample such as WS.  
WS, previously centrifuged, was precipitated using 10 % (w/v) TCA and 0.05% 
DTT. After incubation at 0 °C for one hour, insoluble material was pelleted at 
17000 g. Pellets were washed three times with pure acetone, air dried and 
solubilized in rehydration solution. The protein amount was estimated using an 
RC/DC protein assay from BioRad. This colorimetric assay allows the 
determination of protein concentration in the presence of reducing agents and 
detergents. BSA was used as a standard.  
 
2-DE analysis of preparative gels. 
For first dimension, a preliminary step at 200 V for 12 h was introduced, while 
second dimension is the same as analytical gels. The preparative gels for mass 
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spectrometric analysis were stained with Coomassie Brilliant Blue G-colloidal 
(0,12%Coomassie G-250, 10% ammonium sulfate, 2% phosphoric acid) according 
to Candiano et al. [94]. Briefly, after protein fixation with acetic acid (7%) and 
methanol (40%) for 1 h, the gels were stained overnight with Coomassie Brilliant 
Blue G-colloidal diluted with methanol (4:1 v/v). The gels were then rinsed 60 
seconds with a solution of acetic acid (10%) and methanol (25%)  and finally 
washed twice for few seconds with a solution of methanol (25%). 
Both analytical and preparative gels showed the same protein pattern. Protein 
spots of interest were cut from gel and sent to Core Facility Proteomic (Université 
de Genève) for analysis by MALDI-TOF/TOF.  
 
Western Blot. 
Proteins of interest detected by MS/MS were also identified by Western Blotting 
(WB). WS samples were mixed with SDS sample buffer (Laemmli solution) and 
heated at 100°C for 5 min. Amounts of the samples, corresponding to 50 μg of 
proteins for transaldolase and 2,5 μg for PGAM1, were run on 12 % SDS-PAGE 
gels and transferred onto nitrocellulose membranes (0.2 μm) using a voltage of 
100 V for 30 min (Criterion Blotter, Biorad). Non-specific binding was prevented 
by blocking the membranes with 3% low fat dried milk, 0.2% (v/v) Tween 20 in 
PBS (10 mM NaH2PO4, pH 7.4, 0.9% NaCl) (PBS/milk) overnight at 4°C. After 
blocking, the membranes were incubated for 2 h at RT in PBS/milk containing 
primary antibody transaldolase (goat polyclonal, 1:100 dilution) and 
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phosphoglycerate mutase (mouse monoclonal, 1:200 dilution). After 4 washes 
with PBS/milk, we incubated the membranes with peroxidase-labeled secondary 
antibody (donkey anti-goat, 1:5000 dilution; goat anti-mouse, 1:5000 dilution). 
Proteins were revealed with an enhanced chemiluminescence detection method 
according to the manufacturer’s instructions (PerkinElmer). 
 
SELDI-TOF-MS. 
The experiments with SELDI-TOF-MS were carried out with an approach revised 
on the basis of the advices obtained from the Plate-forme de Protéomique 
Clinique (Montpellier; Prof. Silvain Lehmann) and the GIGA center (Liège; Dr. 
Dominique de Seny). We used two different Protein Chip Arrays (Bio-Rad): 
CM10 (that captures proteins with positive surface charges) and IMAC30 
(Immobilized Metal Affinity Capture, for proteins that bind polyvalent metal 
ions). Aliquots of WS (corresponding to 20μg) were mixed (2:3 v/v) with 
denaturing buffer solution (9M urea, 2% CHAPS) and incubated for 30 min 
before loading onto Protein Chip arrays. Each chip was prepared according to 
Bio-Rad instructions. We first washed the chips two times with the binding 
buffers specific (100 mM sodium acetate pH 4 for CM10; PBS, NaCl 0.5M, Triton 
0.1% for IMAC30) then we applied on the spots the sample. The chips IMAC30 
need also an activation with copper sulphate 100 mM before the wash with the 
binding buffer. After an incubation of 1h, under agitation, the chips were washed 
three times with the specific binding buffer, twice with 150 µL of HEPES (10mM, 
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pH7.0) and then air-dried for 5 min. Finally 1µL of a 50% saturated solution of 
SPA in 50% ACN, 1%TFA was applied twice to each spot to facilitate desorption 
and ionization. The chips were read on a ProteinChip SELDI reader (Personal 
Edition, Bio-Rad). using an automated protocol (laser energy 3500 nJ; matrix 
attenuation 1000; focus mass 10 kDa; acquired mass range from 0 to 100 kDa). 
Analysis of the spectra was carried out using Protein Chip data manager software 
3.5. Spectra were visually examined and poor quality spectra were excluded from 
further analysis. 
Pre-processing of data is required before analysis. These processing steps include: 
calibration, baseline subtraction, normalization and peak detection. Calibration, 
carried out according to the manufacture’s instructions, is necessary for mass 
accuracy. The software was externally calibrated using All-in-One Protein 
Standard and All-in-one Peptide Standard (BioRad). Baseline subtraction was 
achieved by using an algorithm that eliminates any baseline signal caused by 
matrix distortions. Peak intensities were normalized between samples in each 
study group to the total ion current (TIC) for avoiding the signal interference 
from SPA. Auto-detection of peaks was performed with “expression difference 
mapping” (EDM) under the following conditions: signal/noise ratio of 3 or higher 
for the first pass, 2 for the second pass, presentation in at least 10% of spectra for 
identification, 0.1% mass window and mass range 2,000-100,000 Da. Peaks 
having a m/z ratio <2 KDa were not used for analysis because they overlap with 
SPA signal. 
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Statistical Analysis. 
The data of SELDI-TOF-MS were analyzed by an univariate and 2 multivariate 
analysis: extremely randomized trees machine learning algorithm (extra-trees) 
and Tree Boosting algorithm.  
The univariate analysis determines if the intensity of a peak is significantly 
different in the experimental group spectrum as compared to controls; p-values 
associated with every peak were calculated using the Mann–Whitney test 
(significant when <0.05). 
The multivariate analysis were performed by the GIGA Bioinformatics Platform 
& Bioinformatics and Modeling Unit (Université de Liège-Belgium) as described 
by Geurts et al. [95]. 
We used multivariate analysis to build classification models (“predictive models”) 
and extract potentially relevant peaks with variable importance < 1% for tree-
based methods. Biomarkers were thus ranked according to their importance (%) 
provided by the machine learning method. To assess accuracy, it was used the 
leave-one-out protocol. It consists in building a model using all the individuals 
except one, and classifying the remaining individual with the model. The 
procedure is repeated for all individuals to count the overall frequency of 
different types of error and finally it’s provide the sample misclassification error 
rate.  
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RESULTS and DISCUSSION 
Results of 2-DE analysis. 
Figure 1 shows the typical WS 2-DE pattern obtained from a healthy control 
subject (fig.1 A) and from a FM patient (fig.1 B), respectively. 
 
 
 
 
 
 
 
 
 
 
Figure 1: Representative 2-DE gel map of salivary proteins Control (A) and a FM patient (B). A 
total of 150 μg proteins were separated by 2-DE using 18 cm pH 3–10L strip and 12.5% SDS-
PAGE. Proteins were detected by silver staining. The map was analyzed by the Image Master 2-D 
Platinum Software. Spot numbers indicate all the proteins differentially expressed in FM with 
respect to the control, identified by MS/MS and refer to the number reported in Table 5. 
  
 
To assess intra-class variability the correlation coefficients were measured (FM 
patients’ correlation coefficients 0.75–0.86; healthy subjects’ correlation 
coefficients 0.77–0.90). The analysis of the obtained protein profiles allowed us to 
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focus many quantitative and qualitative differences in WS pattern between the 
two groups. A list of identified proteins, MW, pI, score and coverage values of 
MS/MS, fold of change in expression level and p-value calculated using the 
Mann-Whitney test, are shown in table 5.  
 
Table 5. Protein identification of differentially expressed proteins in WS of FM patients by MS/MS.  
(n.s. not significant). 
Spot 
n° 
Protein name 
Accession 
number 
Mw 
KDa 
pI score 
coverage 
(%) 
fold-
increase 
p-value 
         
181 gelsolin A2A418 81 5.6 113 2 1.2 n.s. 
253 transaldolase  P37837 38 6.3 181 42 3.02 <0.0001 
326 phosphoglycerate mutase 1 P18669 29 6.7 501 44 2.5 0.0011 
352 
proteasome subunit alpha type-
2 
P25787 26 6.9 38 2 3.4 0.0258 
348 
Rho GDP-dissociation inhibitor 
2 
P52566 23 5.1 126 13 2.0 0.024 
382 
haptoglobin-related protein 
precursor 
P00739 39 6.4 96 9 5.2 0.0029 
389 cofilin-1 P23528 19 8.2 98 22 2.7 0.069 
405 cyclophilin A P62937 18 7.7 242 40 2.1 0.05 
407 cyclophilin A P62937 18 7.7 450 58 2.1 0.0157 
420 profilin-1 P07737 15 8.4 400 43 2.0 0.0176 
452 calgranulin A P05109 11 6.5 313 47 2.6 0.0036 
455 calgranulin A P05109 11 6.5 187 37 4.7 0.0002 
474 calgranulin C  P80511 11 5.8 68 7 12.9 0.001 
 
 
Figure 2 shows the enlarged images of spots differentially expressed and the 
histogram of the percentage volumes of the proteins found in different quantity 
in FM respect to controls. The representative peptide spectra from three proteins 
among these differentially expressed are shown in Fig. 3. 
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Figure 2: Enlarged images of the 2-DE gels highlighting the differentially expressed proteins for 
four representative gels. The arrows indicate the position of the differentially expressed proteins. 
Histograms show the percentage volumes of the proteins found in significantly different 
quantities in WS of FM patients with respect to the healthy subjects. Each bar represents the 
mean±SD of the mean of each spot. Significant differences from control WS are based on Mann-
Whitney test; (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 3: Representative peptide MS/MS spectra from three proteins differentially expressed as 
obtained from Scaffold software (Proteome Software, Portland, OR, USA). 
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Transaldolase and PGAM1 ROC curves. 
ROC curve was calculated to evaluate the ability of transaldolase and PGAM1 to 
separate patients and control groups (Fig. 4). The sensitivity and the specificity of 
the transaldolase and PGAM1 were respectively 77.3 and 84.6% and 95.5 and 
50%. No statistically significant correlation was detected between transaldolase 
and PGAM1 expression and any of the following FM clinical parameters: FIQ (p-
value=0.98 for transaldolase and p-value=0.71 for PGAM1, respectively), visual 
analogic scale (VAS) (p-value=0.16 for transaldolase and p-value=0.47 for 
PGAM1, respectively) and the number of tender points (p-value=0.89 for 
transaldolase and p-value=0.94 for PGAM1, respectively). 
 
Figure 4: ROC curve of transaldolase and PGAM1. 
 
 
The obtained results were validated by WB analysis of the WS proteins in 63 FM 
patients with respect to 63 control subjects. As depicted in Fig. 5, each antibody 
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recognized a specific band, corresponding to the molecular weight of the relative 
protein: 28KDa for PGAM1 and 38KDa for transaldolase. The optical density of 
specific band was detected by the software ImageJ and the mean ±SD values were 
compared between the two groups. Data are showed in the bar graphs (Fig. 5). 
The analysis, performed with Mann-Whitney test, of total optical density 
confirmed the significant up-regulation of transaldolase and PGAM1 in FM 
samples with respect to healthy subjects: p=0.02 and p=0.006, respectively (fig. 5, 
bar graph). 
 
 
Figure 5: Western Blot analysis of transaldolase and PGAM1 in WS samples from healthy subjects 
(CTRL), and FM patients. Densitometry of the blots is shown. Values that are significantly 
different from healthy subjects (p<0.05) as determined by Mann-Whitney test, are indicated.  
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We have also investigated the correlation of the expression of transaldolase and 
PGAM1 between FM patients without psychiatric disorders and FM patients with 
concomitant psychiatric disorders. Figure 6 shows the histograms of the optical 
density (mean ±SD) of these proteins detected with WB analysis. We have 
evaluated the differences between five classes of FM patients: FM without 
psychiatric comorbidity (FM no psy), anxiety disorder, panic disorder, depression 
and bipolar disorder. We have excluded FM patients with more than one 
concomitant psychiatric disorder. The analysis, performed with Mann-Whitney 
test, of total optical density reveals an up-regulation of PGAM1 in FM patients 
with anxiety disorder respect to “FM no psy” patients: p-value=0.03. But also 
transaldolase shows a tendency to increase in FM patients with anxiety disorder 
respect to “FM no psy”: p=0.06 (fig.6) 
 
 
 
 
 
 
 
 
Figure 6: Histograms of the optical density (mean±SD) of transaldolase and PGAM1 detected with 
WB analysis in WS samples. We reported the different classes of patients: FM without psychiatric 
comorbidity (FM no psy), anxiety disorder, panic disorder, depression and bipolar disorder. Values 
that are significantly different (p<0.05) as determined by Mann-Whitney test, are indicated.  
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Discussion of 2-DE analysis. 
With this study we described the human WS protein pattern of FM patients in 
comparison with healthy controls in order to identify the potential salivary 
biomarkers for the disease. The most relevant observation, which emerged from 
the data analysis, is the significant over-expression of transaldolase (spot n°253) in 
FM patients with respect to control. Transaldolase is an enzyme of the non-
oxidative phase of the pentose phosphate pathway, which is involved in the 
generation of nicotinamide adenine dinucleotide phosphate reduced (NADPH) 
[96]. Many evidences have shown that oxidative stress and nitric oxide may play 
an important role in FM pathophysiology [97]. However, it is still not clear 
whether oxidative stress abnormalities documented in FM are the cause or the 
effect [98, 99, 100].  
The overexpression of transaldolase might be justified by the nicotinamide 
adenine dinucleotide phosphate reduced production, which could be involved in 
limiting oxidative damage to tissues. Transaldolase with a sensibility of 77.3% and 
a specificity of 84.6% may then be considered a reliable biomarker for FM (Fig. 
4). Moreover, transaldolase links the pentose phosphate pathway to glycolysis. 
From this point of view, it is intriguing that another enzyme involved in the 
glycolysis, the PGAM1 (spot n°326), was differently expressed in FM patients 
[101].  
We investigated the expression of these two proteins also in the 4 main 
psychiatric subsets of FM patients: anxiety disorder, panic disorder, depression 
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and bipolar disorder. Optical density of transaldolase and PGAM1 detected by 
WB in these patients was compared with that of FM patients without psychiatric 
comorbidity (fig.6).  
With regard to transaldolase we can observe a tendency to up-regulation in FM 
patients with anxiety disorders respect to “FM no psy” patients, while the 
increase of PGAM1 in patients with anxiety disorders respect to “FM no psy” 
patients is significant.  
These data are interesting considering a recent work of Gormanns and 
collaborators [102]. In order to capture the complex pathophysiology of anxiety 
and depression, they conducted a comprehensive pathway analysis taking into 
account all relevant transcriptome data currently deposited in the public domain. 
In case of anxiety disorder, besides a dysregulation of carbohydrate metabolism, 
tight junction, phosphatidylinositol signaling system, vascular endothelial growth 
factor (VEGF) signaling and long term potentiation they found a dysregulation of 
glycolysis pathway. Even if we had few samples to speculate any conclusion, our 
preliminary results can give us interesting indications for future studies. 
Besides these proteins also cyclophilin A (CyPA) (spots n°405, 407), calgranulin A 
(spots n°452, 455) and calgranulin C (spot n°474) resulted all over-expressed in 
FM patients in comparison with healthy subjects. CyPA is a ubiquitously 
distributed protein belonging to the immunophilin family and it is recognized as 
the host cell receptor for the potent immunosuppressive drug cyclosporine A 
[103]. CyPA has also been shown to possess peptidylprolyl cis-trans-isomerase 
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activity and it is thought to play an important role in protein folding [103]. 
Although CyPA was initially believed to exist solely as an intracellular protein, 
later studies have revealed that it can be secreted by cells in response to 
inflammatory stimuli [104]. Secreted CyPA is a potent chemo attractant for 
monocytes, neutrophils, eosinophils and T cells in vitro. Recently, Satoh K and 
co-workers [105], showed that CyPA is secreted from smooth muscle cells and 
macrophages also in response to oxidative stress [104, 105, 106]. Calgranulins are 
highly homologous low-molecular weight calcium-binding proteins belonging to 
the S100 multigene family of proteins implicated in regulating calcium-
dependent intracellular processes [107].  
S100 proteins are involved in a variety of intracellular activities, cell proliferation 
and differentiation, cytoskeletal interactions, rearrangement and structural 
organization of membranes, intracellular Ca2+ homeostasis, cell migration, 
inflammation and protection from oxidative cell damage [108, 109]. Considering 
that FM is defined as a non-inflammatory disease, we suggest that the over-
expression of calgranulins in association with the other above mentioned 
biomarkers might be related more to the increased oxidative stress in FM rather 
than to an inflammatory process. According to the non-inflammatory nature of 
the disease another relevant observation is related to the gelsolin (GSN) 
expression (spot n°181). GSN was identified in 16 out of 22 salivary samples of 
patients affected by FM and in 10 out of 26 healthy controls. Nonethelesss, from a 
quantitative point of view, the protein was expressed in FM at the same levels as 
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in the healthy volunteers (p-value=0.18). GSN is a ubiquitous cytoplasmic actin-
binding protein that mediates cell shape changes and motility [110, 111]. 
Recently it has been demonstrated that in every acute tissue injury (lung injury, 
adult respiratory distress syndrome, acute liver injury, myonecrosis, synovitis, 
pancreatitis, trauma, burns and bacterial sepsis) plasmatic GSN levels decrease 
[111, 112, 113, 114, 115, 116]. The unifying explanation for low plasmatic GSN 
concentrations in acute inflammatory conditions is the exposure by injury to 
plasma of the GSN-binding ligand, actin, a major cellular constituent ordinarily 
separated from the extracellular environment by intact plasma membranes [115]. 
The fact that in this study FM patients salivary levels of GSN were comparable 
with those of healthy controls is in line with the non-inflammatory nature of FM. 
In addition to GSN, other proteins involved in the cytoskeletal arrangement 
appeared to be differently expressed. In particular, profilin 1 (spot n°420) was 
overexpressed (p-value=0.017), while cofilin (spot n°389) showed the tendency to 
increase (p-value=0.06). Both of this actin binding proteins, even if in a different 
way, are responsible for the dynamics of filament turnover and remodeling of the 
actin cytoskeleton in response to appropriate signals [117]. Finally, three other 
proteins, Rho GDP-dissociation inhibitor 2 (spot n°348), proteasome subunit-a-
type-2 (spot n°352) and haptoglobin-related protein precursor (spot n°382) 
resulted over-expressed with, respectively, two-, three and five-fold of increase in 
WS of FM patients with respect to the control subjects. Rho GDP-dissociation 
inhibitor 2 is a pivotal regulator of Rho GTPases, which are involved in the 
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control of cell morphology and motility in untrasformed cells [118, 119, 120]. 
Proteasome is a cytoplasmatic as well as nuclear-localized proteinase complex 
that is involved in the ubiquitin-dependent selective degradation of short-lived 
and abnormal proteins [121, 122]. Haptoglobin-related protein is a specific plasma 
protein associated with apolipoprotein L–I containing high-density lipoprotein 
particles shown to be a part of the innate immune defense [123]. The role of these 
proteins in FM patients need to be clarified. In conclusion, this first, preliminary 
study investigating salivary biomarkers in FM adds to the growing body of 
evidence that WS analysis performed by combining 2-DE and MALDI-TOF/TOF 
may be a new useful tool in the search for a potential panel of biomarkers in 
systemic diseases. In this study, patients’ human saliva allows us to focus on some 
of the peculiar pathogenic aspects of FM, and namely, the non-inflammatory 
nature of the disease, the oxidative stress which contradistinguishes this 
condition and the involvement of proteins related to the cytoskeletal 
arrangements. None of the candidate proteins showed a statistical correlation 
with the patients’ clinical features (i.e. FIQ, VAS, tender points). Further studies 
are desirable to assess any potential clinical correlation between the candidate 
biomarkers and the different subsets of FM patients, and to evaluate the potential 
therapeutic implication of our results. 
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Results of SELDI-TOF-MS analysis. 
Protein expression profiles for each sample were generated also by SELDI-TOF-
MS that provides a complementary visualization technique of the 2-DE.  
Figure 7 reports a representative protein profile of salivary samples by using 
CM10 ProteinChips in the molecular range of 0–50 kDa. 
 
 
 
 
 
Figure 7: Representative protein profile of salivary samples by SELDI-TOF-MS using CM10 
ProteinChips in the molecular range of 0–50 kDa. 
 
 
 
SELDI-TOF-MS is often criticize for its poor reproducibility, so it’s mandatory to 
perform at the same time all the experiments with the same chip for the different 
classes, furthermore the use of quality controls (QC) is highly recommended. QC 
is a well-characterized pool of samples processed alongside the experimental 
samples in order to calculate coefficient of variation (CV) for peak intensities and 
mass accuracy as a measure of reproducibility of the SELDI-TOF-MS analyses. 
The QC samples were applied randomly on different chips in order to avoid any 
artefact due to experimental handling. The CV (the standard deviation of the 
series divided by the mean of the series) was calculated using multiple protein 
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intensity, 0.008% for mass accuracy with the CM10 chips and 18.9% for peak 
intensity, 0.003% for mass accuracy with the IMAC30 chips. Our CVs indicated 
acceptable reproducibility of the spectra.  
Peak detection with the ProteinChip data manager software 3.5 resolved a total of 
112 peaks on CM10 and 98 peaks on IMAC30 arrays in the m/z ratio between 
2000 and 100,000. Each spectra was thus described by 112 (CM10) and 98 
(IMAC30) input variables where each variable correspond to the peak intensity 
for the given m/z. Extra-trees and tree boosting analysis provided information 
about peaks which presented high potential of discrimination between FM and 
control. 
Discussion of SELDI-TOF-MS analysis. 
With decision trees it is possible to compute from a tree the contribution of each 
variable to the classification. For each variable, this measure gives the percentage 
of information provided by the tree about the classification that can be attributed 
to this variable. Like the p-value, this measure allows m/z values to be ranked 
according to their relevance for differentiating FM from control groups. 
However, unlike the p-value approach, which takes into account each variable 
individually, this approach considers all variables simultaneously, and hence it 
can take into account interactions among variables.  
Both approaches may thus provide substantially different results [95]. Table 6 
provides the peaks found differentially expressed in FM respect to controls using 
the Mann–Whitney test (significant when p-value<0.05). 46 peaks were found 
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significantly differentially expressed in WS of FM patient respect to controls with 
CM10 arrays and 48 with IMAC30 arrays. 
Table 6: Peaks found differentially expressed (p-value<0.05) 
in FM respect to ctrl using the Mann–Whitney test. 
CM10  IMAC30 
 m/z p-value  m/z p-value 
11569 1.14x10-5  10946 6.14x10-7 
9919 1.19x10-5  22968 1.87x10-6 
7112 2.46x10-5  11615 2.29x10-6 
13178 3.47x10-5  10595 3.43x10-6 
6841 6.12x10-5  22436 3.20x10-5 
8867 6.12x10-5  5111 4.92x10-5 
7482 7.51x10-5  24915 7.40x10-5 
7857 8.66x10-5  9808 8.66x10-5 
7548 0.0002  14724 8.79x10-5 
5512 0.0003  8956 0.0001 
10830 0.0003  11025 0.0002 
11035 0.0004  8985 0.0002 
22922 0.0006  24089 0.0003 
13459 0.0007  5403 0.0003 
9799 0.0008  7511 0.0004 
12689 0.0008  9106 0.0004 
24008 0.0008  10864 0.0005 
12770 0.0009  6249 0.0006 
7528 0.0012  14331 0.0006 
5424 0.0017  11047 0.0006 
9429 0.0018  28603 0.0007 
7241 0.0020  7163 0.0008 
5019 0.0028  9969 0.0008 
9963 0.0028  8578 0.0016 
5454 0.0029  29737 0.0016 
14694 0.0032  3291 0.0027 
5225 0.0035  8854 0.0039 
13354 0.0040  4717 0.0048 
8256 0.0041  15895 0.0050 
8571 0.0044  7861 0.0052 
51947 0.0046  4140 0.0067 
4141 0.0063  4246 0.0080 
6351 0.0069  12179 0.0087 
11004 0.0074  4822 0.0103 
5110 0.0103  9071 0.0107 
13275 0.0103  3162 0.0146 
1695 0.0163  23522 0.0149 
4936 0.0163  4932 0.0194 
5141 0.0174  6647 0.0203 
16437 0.0246  6405 0.0212 
12160 0.0320  11535 0.0266 
9865 0.0340  27558 0.0306 
18044 0.0397  66928 0.0353 
11143 0.0416  5705 0.0411 
16522 0.0416  15566 0.0411 
2235 0.0421  28130 0.0421 
   31152 0.0480 
   10457 0.0496 
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Tables 7 and 8 illustrate the first 15 most discriminating peaks obtained with the 
two methods on CM10 and IMAC30 arrays. The quantity of information that a 
peak brings in the ensemble decision trees was referred as the percentage of 
importance (imp%) and was used to rank the potential biomarkers. We also 
provided in these tables the p-values calculated by univariate analysis with the 
Mann–Whitney test for these peaks. We then made the assumption that highly 
informative peaks were good biomarker candidates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7: The 15 most discriminating biomarkers, on CM10 arrays, ranked 
according to imp (%) determined by Extra-trees and Tree-boosting and 
associated p-value calculated by Mann–Whitney test. 
FM vs CTRL 
Extra-trees  Tree-boosting 
m/z imp% p-value  m/z Imp% p-value 
11569 3.8 1.14x10-5  11569 11.49 1.14x10-5 
4934 3.34 0.0162  7112 4.71 2.46x10-5 
9799 2.94 0.000754  7548 4.28 0.00019 
7859 2.54 8.66x10-5  3447 4.11 0.3526 
5138 2.41 0.01737  7859 3.81 8.66x10-5 
7112 2.37 2.46x10-5  8852 3.53 6.12x10-5 
3447 2.27 0.3526  9799 2.9 0.000754 
5851 2.06 0.13226  13178 2.56 3.47x10-5 
13178 2.00 3.47x10-5  6840 2.08 6.12x10-5 
8852 2.00 6.12x10-5  5851 2.05 0.13226 
7548 1.74 0.00019  22968 1.82 0.000609 
8309 1,68 0.579723  7528 1.6 0.001166 
3375 1,66 0.190174  5454 1.56 0.002894 
3491 1.54 0.775312  4716 1.55 0.397251 
5021 1.46 0.002803  52077 1.44 0.00462 
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Table 9 reports the predictions of these statistical analysis with the error rate, the 
error rate is the percentage of samples that are misclassified by the model. 
Table 9: Predictions made with two different multivariate analysis. 
CM10 
EXTRA-TREE  TREE BOOSTING 
Error rate: 35.714%  Error rate: 27.778% 
GROUP FM CTRL TOTAL  GROUP FM CTRL TOTAL 
FM 42 21 63  FM 48 15 63 
CTRL 24 39 63  CTRL 20 43 63 
TOTAL 66 60 126  TOTAL 68 58 126 
IMAC30 
Error rate: 32.54%  Error rate: 29.365% 
GROUP FM CTRL TOTAL  GROUP FM CTRL TOTAL 
FM 43 20 63  FM 46 17 63 
CTRL 21 42 63  CTRL 20 43 63 
TOTAL 64 62 126  TOTAL 66 60 126 
Table 8: The 15 most discriminating biomarkers, on IMAC30 arrays, ranked 
according to imp (%) determined by Extra-trees and Tree-boosting and 
associated p-value calculated by Mann–Whitney test. 
FM vs CTRL 
Extra-trees  Tree-boosting 
m/z imp% p-value  m/z imp% p-value 
11615 5.17 2.293x10-6  11615 11.82 2.293x10-6 
10595 3.10 3.429x10-6  5769 4.39 0.0609 
10945 2.83 6.137x10-7  3446 3.85 0.7042 
3446 2.7 0.7042  5110 3.76 4.294x10-5 
5769 2.31 0.0609  9808 3.30 8.66x10-5 
5110 2.03 4.294x10-5  4716 2.87 0.00481 
8955 2.03 0.000125  22967 2.77 1.87x10-6 
10864 2.02 0.00049  14724 2.75 8.79x10-5 
9106 1.99 0.00045  10945 2.73 6.137x10-7 
4932 1.99 0.01939  7861 2.3 0.00525 
2115 1.85 0.33347  5402 2.26 0.0003 
9808 1.74 8.66x10-5  9969 2.25 0.0008 
4821 1.68 0.0103  10595 2.01 3.429x10-6 
3490 1.54 0.51279  8955 2.00 0.0001 
46918 1.46 0.61715  5222 1.97 0.1009 
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Therefore, with CM10 arrays, using the Extra-tree methods, 81 objects were 
correctly classified and 45 misclassified while, with the Tree-Boosting, 91 samples 
were correctly classified and 35 misclassified. 
With IMAC30 arrays, 85 objects were correctly classified and 41 misclassified 
using Extra-tree analysis; 89 and 37 samples were, respectively, correctly 
classified and misclassified using the Tree Boosting analysis.  
We can observe that for a given statistical approach, the most discriminating m/z 
values provided by the multivariate analysis were not necessarily identical to 
those provided by the p-value (see tables 7, 8). For example the peak with m/z 
3446 Da was 3rd and 4th according to two different multivariate analysis (Tree-
boosting and Extra-tree respectively) but its variation is not significant between 
FM and control according to Mann–Whitney test. Therefore a careful analysis of 
the generated data allowed us to focus our attention on some peaks: those for 
which there is a concordance between the different statistical analysis performed. 
Table 10 underlines the potential biomarkers detected with CM10 and IMAC30 
arrays; p-value and fold variation of intensities of peaks are reported. Some of 
these peaks are illustrated in figure 8. 
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In conclusion, SELDI-TOF-MS is a high-throughput method that compares 
expression levels of many individual proteins from multiple samples in parallel. 
Its strengths are the simple, rapid sample preparation and the use of small amount 
of proteins, so it can play an important role in discovering biomarkers but it does 
not allow identifying proteins. Further study are necessary to purify and identify 
potential biomarkers.  
 
Table 10: Potential biomarkers detected on CM10 and IMAC30 arrays. 
FM vs CTRL 
m/z 
imp%  
extra-trees 
imp%  
Tree-Boosting 
 FM vs ctrl p-value 
CM10 
7112 2.37 4.71 ↑  2.46x10-5 
7548 1.74 4.28 ↑ 0.00019 
7859 2.54 3.81 ↑ 8.66x10-5 
8852 2.00 3.53 ↑ 6.12x10-5 
9799 2.94 2.9 ↑ 0.000754 
11569 3.8 11.49 ↑ 1.14x10-5 
13178 2.00 2.56 ↑ 3.47x10-5 
IMAC30 
5110 2.03 3.76 ↓  4.294x10-5 
5769 2.31 4.39 ↓ 0.0609 
8955 2.03 2.00 ↑ 0.000125 
9808 1.74 3.30 ↑ 8.66x10-5 
10595 3.10 2.01 ↑ 3.429x10-6 
10945 2.83 2.73 ↑ 6.137x10-7 
11615 5.17 11.82 ↑ 2.293x10-6 
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Figure 8: Enlarged image of 4 peaks with significant changes in the FM patients respect to the 
controls. 
 
Future perspectives. 
Our study has attested the potential usefulness of the proteomic characterization 
of human saliva in distinguishing FM from healthy subjects but the panel of 
candidate biomarkers found need to be validated in different cohort of 
pathological controls. Our interest is to compare FM patients with subjects 
affected by other disease in order to identify biomarkers really specific of FM and 
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to exclude any interference of concomitant disorder (e.g. psychiatric 
comorbidities).  
With this aim we have begun to recruit patients affected by inflammatory 
diseases, psychiatric diseases and migraine.  
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